Background. Current PIDS/IDSA guidelines recommend the use of MRSA empiric coverage in the case of hospital acquired pneumonia (HAP) and in community acquired pneumonia (CAP) if patients have risk factors or clinical characteristics consistent with MRSA infection. Retrospective studies in adult patients have shown the MRSA PCR nasal swab to have a negative predictive value of 99% in patients treated for pneumonia in the inpatient setting, making the MRSA nasal swab a potential tool to guide de-escalation of empiric antibiotics. No published studies to date have examined the sensitivity and specificity of MRSA PCR nasal swab in pediatric populations Methods. A cohort of patients was identified by cross-matching internal physician and laboratory billing data from the past 10 years at IU hospitals in the Indianapolis area for pneumonia. An initial pool of 550 patients were identified. Patients less than 25 years of age were eligible. Patients were excluded if they had medical conditions such as Cystic Fibrosis, Chronic Lung Disease, or cavitary pneumonia seondary to IV drug use. Chart review identified a total of 28 patients that met diagnostic criteria for pneumonia, had culture data and had a MRSA PCR nasal swab performed during treatment.
Results. In the cohort, 5 patients had positive MRSA nasal swab and positive cultures for MRSA. Two patients had positive MRSA swab with negative cultures. Twentyone patients had negative MRSA nasal swabs and cultures without MRSA growth. No patients were identified with a negative MRSA nasal swab that grew MRSA in cultures. In this population the MRSA nasal swab had a sensitivity of 100%, specificity of 91%, positive predictive valve of 71%, and a negative predictive value of 100%. The patients with negative MRSA swab and negative cultures, 66% were treated with vancomycin. If MRSA nasal PCR was used to guide treatment, 71% of the patients with a negative nasal swab had potential to discontinue MRSA empiric antibiotics sooner.
Conclusion. The MRSA PCR nasal swab has a high negative predictive valve in this pediatric population of inpatients treated for HAP/CAP. This is consistent with results from adult studies. The high negative predictive valve makes the MRSA PCR nasal swab a potential tool as a rapid diagnostic test to guide empiric antibiotic therapy.
Disclosures. specifically from wound specimens and in acute osteoarticular infections (OAI) were compared with available antibiograms at a freestanding children's hospital.
Methods. Encounter, billing, and electronic microbiology surveillance data were utilized to identify SA wound cultures and acute OAI (osteomyelitis and septic arthritis) cases at Women and Children's Hospital of Buffalo, from 2013 to 2016. OAI cases' medical records were reviewed to ensure diagnostic accuracy. SA wound and OAI specific data were tabulated and compared with published institutional antibiograms. General pediatric locations were defined as community clinics, the emergency room, and general pediatric wards, with intensive-care and oncology units excluded.
Results. Significant discordance existed between general pediatrics SA susceptibilities in the aggregate antibiograms, with both wound cultures and OAI cases, for all 4 years: Figures 1 and 2. The proportion of SA that was methicillin-susceptible (MSSA) was consistently higher in wound specimens than in aggregate data (e.g., 63% vs. 53% in 2016; p≤ 0.01), and is increasing: 63% in 2015-16 vs. 53% in 2013-14, p ≤0.01. Clindamycin (clinda) susceptibility for all SA (MSSA + MRSA) was higher in wound cultures than aggregate data, 89% vs. 82% for 2013-2015 (p ≤ 0.01). For OAI cases, the proportion of MSSA was consistently ~20% higher than in aggregate data (2016: 79% vs. 53%, P = 0.05), and clinda susceptibility for all SA in this group appears to be decreasing: 83% in 2015-16 vs. 96% in 2013-14, P = 0.13.
Conclusion. While our institutional antibiograms created uncertainty, a wound culture review indicated that clinda remains an appropriate empiric choice for community-onset skin and soft-tissue infections. Conversely, an OAI specific analysis revealed a predominance of MSSA and higher rates of clinda-resistant SA, leading us to reappraise the empiric use of clinda in this subset. Pediatric facilities should emphasize stratified, specimen and clinical-context specific-rather than aggregate-antibiograms, especially for SA. Background. Outpatient acute respiratory tract infections (ARTIs) account for the majority of antibiotic exposure in children. Thus, is is essential to understand the outcomes and adverse effect profiles of different therapeutic approaches to managing these common infections. In a study comparing the effectiveness of narrow-and broad-spectrum antibiotics for treatment of ARTIs, we compared rates of adverse effects reported by patients to rates obtained by the electronic health record.
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Adverse Effects from Antibiotics for Acute Respiratory Tract Infections in
Methods. We used a retrospective cohort and a prospective cohort, both of which included children treated with antibiotics for an ARTI (acute otitis media, Group A streptococcal pharyngitis, acute sinusitis) in a network of 31 pediatric primary care practices. In the retrospective cohort, adverse drug effects including diarrhea, candidiasis, non-candida rash, other allergic reaction, vomiting, and unspecified adverse effects were identified by ICD codes from the electronic health record (EHR). In the prospective cohort, a stratified sample of caregivers were contacted by telephone to complete two structured interviews, one at 5-10 days and one at 14-20 days post diagnosis. At the second interview, the caregiver was asked about the occurrence of diarrhea, rash, upset stomach and vomiting. Propensity-score based full matching was conducted to obtain estimates adjusted for patient and provider characteristics.
Results. Overall, 1038 (3.5%) of the 30086 children in the restrospective cohortexperienced an adverse effect that was captured in the EHR. and 599 (28%) of the 2085 children included in the prospective cohort reported an adverse effect. See the table for analysis results.
Conclusion. Narrow-spectrum antibiotics were associated with a reduced risk of adverse effects compared with broad-spectrum antibiotics in both cohorts. The rate of adverse effects observed in EHR data was nearly 10-fold lower than the rate of patient-reported adverse effects. Methods. A retrospective chart review was conducted of all patients aged 0 to 17 years with RP specimens collected August 2015 through December 2016. An evaluation of the impact of RP results was completed through review of duration or change in antimicrobial therapy, change in patient management, and avoidance of further workup, antimicrobial therapy, or hospital admission. A subgroup analysis was performed for patients less than 60 days of age.
Results. Two hundred and ninety-five pediatric patients had a RP specimen collected during the evaluation timeframe. Ninety-six percent of tests were appropriate based on symptoms and 49% of RP results changed patient management (Table 1) . RP result did not change management in any patients greater than 10 years of age. A pathogen was identified in 66% of specimens, with rhinovirus/enterovirus (53.6%) and respiratory syncytial virus (20.5%) being the most common viruses isolated. The use of the RP was highest in the months of August through December, with viral pathogen isolation being highest in these months as well. In patients less than 60 days of age (n = 40), the RP result changed management in 22 (55%) cases, including 3 avoided admissions, 12 avoided antibiotic courses, and 7 avoided lumbar punctures.
Conclusion.
The use of a RP was beneficial in this pediatric population to decrease hospital admissions, avoid further unnecessary procedures, avoid unnecessary antibiotic therapy, decrease duration of antibiotics and target antimicrobial therapy. Further consideration should be given to implement an algorithm for use.
Disclosures. M. F. Williams, BioFire Diagnostics: Consultant, Speaker honorarium; Joint Commission Resources: Consultant, Speaker honorarium Friday, October 6, 2017: 12:30 PM Background. In 2014, the AAP updated guidelines for administration of palivizumab in children at high risk of respiratory syncytial virus (RSV) disease. The updated guidelines defined high risk patient populations and recommended that eligible inpatients not receive monthly palivizumab prophylaxis but may receive a dose 24-72 hours prior to discharge. In a freestanding children's hospital, the ASP developed a protocol that ensured compliance with the adoption of these guidelines through prospective audit of all palivizumab orders prior to medication dispensing. Review of 2 seasons of palivizumab inpatient protocol dosing was compared with historical baseline drug utilization.
Cost Analysis of an Antimicrobial Stewardship Program (ASP) Protocol for Adherence to the 2014 American Academy of Pediatrics (AAP) Palivizumab Prophylaxis Recommendations in a Freestanding
Methods. All palivizumab orders required an indication that was reviewed by a pharmacist who confirmed the patient's medical condition(s) and eligibility prior to medication dispensing. The pharmacist verbally reconciled any discrepancies with the ordering provider and if patient did not meet AAP guideline criteria, two members of the ASP reviewed the order and patient's medical record to determine inpatient eligibility for palivizumab administration. Two RSV seasons of palivizumab inpatient dosing were compared with the baseline year prior to protocol adoption to analyze impact of the protocol on direct costs of palivizumab to the organization.
Results. Two hundred and seventy-seven inpatient doses of palivizumab were reviewed from November 1, 2014 to April 30, 2017. After implementation of the palivizumab protocol, the number of doses administered decreased each RSV season (see Figure 1 ). This resulted in a decrease in drug expenditures in each of the post implementation seasons (see Figure 2) . The ASP reviewed orders for 10 patients during the 2015-2016 season and 16 patients during the 2016-2017 season for unapproved indications. Hospital-acquired RSV infections remained stable after protocol implementation and isolation recommendations were unchanged.
Conclusion.
In a freestanding children's hospital, an ASP driven protocol reduced palivizumab administration to inpatients in keeping with AAP guidelines while reducing direct pharmacy costs and without an increase in hospital-acquired RSV infections during the evaluation period.
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